TEVA PHARMACEUTICAL IND LTD

Teva Pharmaceutical Industries (TEVA.TA) saw a 2.1% dip to ILS 124.1 on Oct 23, 2026, amid mixed peer moves; analysts eye upcoming earnings for a possible buying window.

Teva Pharma shares dip 2.1% as new duvakitug data boost investor confidence, showing promising long‑term remission in ulcerative colitis and Crohn’s disease.

Teva Pharma’s stock rises 0.86% amid a bullish trend, backed by strong pipeline and cost cuts, positioning it as a top pick for pharma investors.